4//SEC Filing
Shukla Sath 4
Accession 0000899243-22-030087
CIK 0001701108other
Filed
Aug 29, 8:00 PM ET
Accepted
Aug 30, 5:00 PM ET
Size
5.9 KB
Accession
0000899243-22-030087
Insider Transaction Report
Form 4
Shukla Sath
CEO & President
Transactions
- Sale
Common Stock
2022-08-29$0.89/sh−6,017$5,378→ 56,064 total
Footnotes (3)
- [F1]The reported transaction is a sale of common stock pursuant to a preexisting 10b5-1 plan upon the vesting on August 26, 2022 of a portion of restricted stock units ("RSUs") granted to the Reporting Person on August 26, 2021.
- [F2]Represents the weighted average sales price per share. The shares sold at prices ranging from $0.8839 to $0.9002 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
- [F3]Consists of RSUs. Each RSU represents the right to receive one share of common stock upon vesting. 18,050 of the RSUs vest in three equal annual installments beginning on August 26, 2023 and 38,014 of the RSUs vest in four equal annual installments beginning on February 1, 2023, in each case subject to the Reporting Person's continued service through the applicable vesting date.
Documents
Issuer
Spero Therapeutics, Inc.
CIK 0001701108
Entity typeother
Related Parties
1- filerCIK 0001782817
Filing Metadata
- Form type
- 4
- Filed
- Aug 29, 8:00 PM ET
- Accepted
- Aug 30, 5:00 PM ET
- Size
- 5.9 KB